Strategic Patenting by Pharmaceutical Companies – Should Competition Law Intervene?
| العنوان: | Strategic Patenting by Pharmaceutical Companies – Should Competition Law Intervene? |
|---|---|
| المؤلفون: | Olga Gurgula |
| المصدر: | International review of intellectual property and competition law, 51(9):1062-1085 IIC-International Review of Intellectual Property and Competition Law Iic; International Review of Industrial Property and Copyright Law |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Coronavirus disease 2019 (COVID-19), Strategic patenting, generic competition, Pharmaceutical patents, COVID-19, Generic competition, Anticompetitive effect, Access to COVID-19 treatment, Access to medicines, Evergreening, Intellectual property, 01 natural sciences, Article, Competition (economics), strategic patenting, 03 medical and health sciences, Market economy, anticompetitive, access to COVID-19 treatment, 0101 mathematics, access to medicines, pharmaceutical patents, evergreening, 010102 general mathematics, Drug prices, Competition law, Intervention (law), 030104 developmental biology, Political Science and International Relations, Business, Consumer welfare, Law |
| الوصف: | As the COVID-19 pandemic is affecting the lives of thousands of people worldwide, the problem of timely access to affordable medicines has intensified today. Based on past experience of accessing medicines for life-threatening diseases there is a justifiable fear that access to any vaccines and treatments that are eventually developed may be hindered by patents, leading to unaffordable prices. In particular, one of the reasons that typically leads to high prices is strategic patenting employed by pharmaceutical companies. While this practice is currently considered lawful, this article argues that strategic patenting requires a long-overdue intervention by competition authorities and aims to attract their attention to its harmful effects. It maintains that, along with a more immediate negative effect in the form of high drug prices, strategic patenting affects dynamic competition by stifling innovation of both originators and generic companies. The article outlines the current approach to strategic patenting and provides arguments for the intervention of competition law. This, in turn, will open the possibility for competition authorities to investigate this practice and prevent its harmful effect on drug prices and pharmaceutical innovation, for the benefit of consumer welfare. |
| وصف الملف: | Print-Electronic |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1cab32c70b1bd9e1f33817aeb4fce08 https://repository.publisso.de/resource/frl:6427564 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b1cab32c70b1bd9e1f33817aeb4fce08 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |